Novasep pours $3.7M into French API plant

CMO Novasep is investing €3 million ($3.7 million) to expand its highly potent active pharmaceutical ingredient production, pouring the cash into its Le Mans, France, facility.

Novasep is looking to bolster its production of anti-cancer APIs, a market the company says has exploded over the past few years. As targeted cancer therapies take the place of traditional chemotherapeutics, Novasep hopes to snag a share of the growing field by increasing its highly potent API capacity, Patrick Glaser, head of Novasep Synthesis, said in a statement.

"Manufacturing for the life science sectors is facing a series of challenges," Glaser said. "Drug candidates become more specific and personalized, whilst the economic climate demands more cost-effective and safe solutions."

The company expects to have its expansion up and running by 2013, replete with cryogenic chemistry technology and large-scale HPLC chromatography.

- read Novasep's release

Suggested Articles

The money will be used to expand its footprint in both China and the U.S., including a new R&D operation in Boston.

Aetion has raised $50 million so far, and it plans to enhance its platform to support more complex therapeutic areas and expand its team.

Charles River partners with PathoQuest to offer clients NGS solutions for biologics viral contamination testing and cell-line genetic characterization.